Navigation Links
Curing more cervical cancer cases may be in the math
Date:1/29/2010

COLUMBUS, Ohio Cervical cancer is highly curable when caught early. But in a third of cases, the tumor responds poorly to therapy or recurs later, when cure is much less likely.

Quicker identification of non-responding tumors may be possible using a new mathematical model developed by researchers at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

The model uses information from magnetic resonance imaging (MRI) scans taken before and during therapy to monitor changes in tumor size. That information is plugged into the model to predict whether a particular case is responding well to treatment. If not, the patient can be changed to a more aggressive or experimental therapy midway through treatment, something not possible now.

The study, published in the journal Cancer Research, uses MRI scans and outcome information from 80 cervical cancer patients receiving a standard course of radiation therapy designed to cure their cancer.

"The model enables us to better interpret clinical data and predict treatment outcomes for individual patients," says principal investigator Jian Z. Wang, assistant professor of radiation medicine and a radiation physicist at the James Cancer Hospital and Solove Research Institute.

"The outcome predictions presented in this paper were solely based on changes in tumor volume as derived from MRI scans, which can be easily accessed even in community hospitals," Wang says. "The model is very robust and can provide a prediction accuracy of 90 percent for local tumor control and recurrence."

A strength of the new model, says first author Zhibin Huang, is its use of MRI data to estimate three factors that play key roles in tumor shrinkage and that vary from patient to patient the proportion of tumor cells that survive radiation exposure, the speed at which the body removes dead cells from the tumor, and the growth rate of surviving tumor cells.

The model is applicable to all cervical cancer patients, and the investigators are developing a model that can be applied to other cancer sites, Wang says.

Coauthor Dr. Nina A. Mayr, professor of radiation medicine at Ohio State, notes that the size of cervical tumors is currently estimated by touch, or palpation, which is often imprecise. Furthermore, shrinkage of a tumor may not be apparent until months after therapy has ended.

Other clinical factors currently used to predict a tumor's response to therapy include the tumor's stage, whether it has invaded nearby lymph nodes and its microscopic appearance.

"Our kinetic model helps us understand the underlying biological mechanisms of the rather complicated living tissue that is a tumor," Wang says. "It enables us to better interpret clinical data and predict treatment outcomes, which is critical for identifying the most effective therapy for personalized medicine."


'/>"/>

Contact: Darrell E. Ward
darrell.ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Curing Diabetes, Pigs Turn to Lions
2. Lumension Audiocast With Aberdeen Group Highlights How to Reduce IT Costs By Effectively Managing and Securing Endpoints
3. Star Scientific Reports on Filing Patent Application for Zero-Nitrosamine Tobacco Curing Process, Product Development by Rock Creek Pharmaceuticals
4. Securing Your Health Care Coverage
5. Talk About Curing Autism Launches Seven New Chapters
6. NLRB Blocks New Organizations Attempts to Divide UHW; SEIU UHW Committed to Securing Good Contracts With Members
7. Talk About Curing Autism Receives $300,000 Grant From Pacific Life Foundation to Provide Services for Families Affected by Autism in Orange County
8. Man Routes 100-Mile Run Securing Health Care for Inner-City Children
9. Naturally-occuring protein may be effective in limiting heart attack injury and restoring function
10. Columbia University Medical Center/NYPH receive $28 million donation toward curing diabetes
11. Curing addiction with cannabis medicines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider ... that a new solution for Emergency Departments (ED) has been added to their ... Emergency Department examination rooms, and with a simplified pallet of information available to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... with distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority ... care and patient safety. Only a few hospitals and facilities have earned this ...
(Date:12/8/2016)... ... December 08, 2016 , ... Seavest ... Property owned by an affiliate of Seavest, has won a prestigious national healthcare ... Chester County ambulatory care center (ACC) was named “Best New Development, MOBs and ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont ... and attorneys from the firm’s global Life Sciences & Medical Technology Group have been ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... the largest share of the market in 2016 and ... dominance can be attributed to a large number of ... (US hold the largest share in the patient temperature ... benefits such as reducing loss of blood during surgeries, ...
(Date:12/8/2016)... 8, 2016 Research and Markets has announced ... Trends - Adhesion Type, Application, Usability - Forecast to 2025" ... , ... Market is poised to grow at a CAGR of around 3.2% ... market is witnessing include advancements in extracellular microelectrode arrays and intracellular ...
(Date:12/8/2016)... Quebec , Dec. 8, 2016  Valeant ... and TSX: VRX) ("Valeant") today announced positive results ... clinical study to assess the safety and efficacy ... the treatment of plaque psoriasis. ... subjects with moderate to severe psoriasis, IDP-118 showed ...
Breaking Medicine Technology: